MFG
ALZN icon

Merit Financial Group’s Alzamend Neuro ALZN Stock Holding History

Merit Financial Group’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-37
Closed -$95K – 383
2021
Q4 		$95K Buy
+37
New +$114K 0.01% 271

Other funds holding ALZN

Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Merit Financial Group's ALZN Position: Q1 2022 in Review

Merit Financial Group sold out of Alzamend Neuro (ALZN) in Q1 2022, closing a stake of 37 shares — an estimated $95K sold.

Merit Financial Group first reported a position in ALZN in Q4 2021 and held it in 1 quarter. The position peaked at $95K in Q4 2021. 20 funds tracked by Wall St. Rank hold ALZN as of Q1 2022.

  • Merit Financial Group reported no remaining Alzamend Neuro position as of Q1 2022 after selling out during the quarter.
  • Merit Financial Group sold 37 Alzamend Neuro shares in Q1 2022, an estimated $95K.
  • Merit Financial Group first reported a position in Alzamend Neuro in Q4 2021 and held it in 1 quarter.
  • Merit Financial Group's Alzamend Neuro position peaked at $95K in Q4 2021.
  • 20 funds tracked by Wall St. Rank held Alzamend Neuro as of Q1 2022.

Based on Merit Financial Group's 13F filing for Q1 2022, filed 13 May 2022.